Eugen Ruckhäberle - Concepedia

Author

Eugen Ruckhäberle

Also Known As

E Ruckhäberle, E Ruckhäberle, E. Ruckhäberle, E. Ruckhäberle, Eugen RUCKHÄBERLE, Eugen Ruckhäberle, Eugen Ruckhäberle, Ruckhäberle, E.

200

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

Goethe University Frankfurt Heinrich Heine University Düsseldorf Düsseldorf University Hospital Universität Hamburg University Medical Center Hamburg-Eppendorf

About

Eugen Ruckhäberle is an author at Goethe University Frankfurt specializing in breast cancer, medicine, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	13	839
2	Cell Biology	8	8	605
3	Engineering	2	2	99
4	Endocrinology	1	1	24
5	Immunology	1	1	46

Eugen Ruckhäberle

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer Eugen Ruckhäberle, Achim Rody, Knut Engels, Breast Cancer Research and Treatment Breast OncologySphingosine Kinase 1MedicineBreast CancerMicroarray Analysis	2007	296
Ceramide synthases and ceramide levels are increased in breast cancer tissue Susanne Schiffmann, Jessica Sandner, Kerstin Birod, Carcinogenesis	2009	229
Gene expression of ceramide kinase, galactosyl ceramide synthase and ganglioside GD3 synthase is associated with prognosis in breast cancer Eugen Ruckhäberle, Thomas Karn, Achim Rody, Journal of Cancer Research and Clinical Oncology Breast OncologyMedicineCeramide KinaseCancer GrowthPathology	2009	95
Homogeneous Datasets of Triple Negative Breast Cancers Enable the Identification of Novel Prognostic and Predictive Signatures Thomas Karn, Lajos Pusztai, Uwe Holtrich, PLoS ONE	2011	92
Diagnostic leukapheresis for CTC analysis in breast cancer patients: CTC frequency, clinical experiences and recommendations for standardized reporting Tanja Fehm, F Meier-Stiegen, Christiane Driemel, Cytometry Part A	2018	82
Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response Achim Rody, Thomas Karn, R. Gätje, The Breast Tumor ResponseBreast OncologyBreast Cancer PatientsMedicinePathology	2006	80
Poor Outcome in Estrogen Receptor–Positive Breast Cancers Predicted by Loss of <i>Plexin B1</i> Achim Rody, Uwe Holtrich, R. Gaetje, Clinical Cancer Research	2007	65
Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer Achim Rody, Thomas Karn, Eugen Ruckhäberle, Breast Cancer Research and Treatment Radiation OncologyBreast OncologyOncologyEngineeringMedicine	2008	61
The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial Achim Rody, Thomas Karn, Christine Solbach, The Breast Breast OncologyErbb2+ ClusterMedicinePathologyCancer Genomics	2007	56
Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany Andreas Schneeweiß, Johannes Ettl, Diana Lüftner, The Breast	2020	54

Page 1